ATE93518T1 - Enantiomere derivate von aminosaeure, verfahren zu deren herstellung und deren therapeutische verwendung. - Google Patents

Enantiomere derivate von aminosaeure, verfahren zu deren herstellung und deren therapeutische verwendung.

Info

Publication number
ATE93518T1
ATE93518T1 AT88402944T AT88402944T ATE93518T1 AT E93518 T1 ATE93518 T1 AT E93518T1 AT 88402944 T AT88402944 T AT 88402944T AT 88402944 T AT88402944 T AT 88402944T AT E93518 T1 ATE93518 T1 AT E93518T1
Authority
AT
Austria
Prior art keywords
amino acid
preparation
therapeutic use
enantiomeric derivatives
enantiomeric
Prior art date
Application number
AT88402944T
Other languages
English (en)
Inventor
Pierre Duhamel
Lucette Duhamel
Denis Danvy
Jean-Christophe Plaquevent
Bruno Giros
Claude Gros
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Application granted granted Critical
Publication of ATE93518T1 publication Critical patent/ATE93518T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT88402944T 1987-11-24 1988-11-24 Enantiomere derivate von aminosaeure, verfahren zu deren herstellung und deren therapeutische verwendung. ATE93518T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8716239A FR2623498B1 (fr) 1987-11-24 1987-11-24 Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
EP88402944A EP0318377B1 (de) 1987-11-24 1988-11-24 Enantiomere Derivate von Aminosäure, Verfahren zu deren Herstellung und deren therapeutische Verwendung

Publications (1)

Publication Number Publication Date
ATE93518T1 true ATE93518T1 (de) 1993-09-15

Family

ID=9357085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88402944T ATE93518T1 (de) 1987-11-24 1988-11-24 Enantiomere derivate von aminosaeure, verfahren zu deren herstellung und deren therapeutische verwendung.

Country Status (7)

Country Link
US (3) US5208255A (de)
EP (1) EP0318377B1 (de)
JP (2) JP2529172B2 (de)
AT (1) ATE93518T1 (de)
DE (1) DE3883495T2 (de)
ES (1) ES2059554T3 (de)
FR (1) FR2623498B1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623498B1 (fr) * 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
US5223516A (en) * 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
FR2673105B1 (fr) * 1991-02-26 1995-01-13 Bioprojet Soc Civ Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.
FI922867A (fi) * 1991-06-21 1992-12-22 Tanabe Seiyaku Co Dikarbonsyraderivat och foerfarande foer framstaellning av dem
FR2684553B1 (fr) * 1991-12-10 1995-04-07 Bioprojet Soc Civ Nouveaux medicaments pour le traitement de l'hypertension arterielle, de l'insuffisance cardiaque chronique, de l'insuffisance renale et, de maniere generale, d'affections entrainant une retention hydrosodee.
JPH06199850A (ja) * 1992-12-28 1994-07-19 Tanabe Seiyaku Co Ltd インドール含有ペプチド及びその製法
US5760241A (en) * 1995-12-28 1998-06-02 Zambon Group S.P.A. Thiol derivatives with metallopeptidase inhibitory activity
FR2744446B1 (fr) * 1996-02-05 1998-04-17 Bioprojet Soc Civ Procede de synthese asymetrique des derives s-acyles de l'acide 2-mercaptomethyl 3-phenyl propanoique, application a la synthese de derives n-(mercaptoacyl) amino-acides
US6121477A (en) * 1996-08-02 2000-09-19 Kaneka Corporation Sulfonic ester derivatives, process for preparing the same, and use thereof
EP0937710B1 (de) 1998-02-16 2003-04-16 Ajinomoto Co., Inc. Verfahren zur Herstellung von optisch aktiven Phenylpropionsäure-Derivat
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009077386A1 (en) 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Process for synthesis of tritiated and deuterated thiorphan and acetorphan
FR2950362B1 (fr) * 2009-09-21 2011-10-21 Univ Clermont Auvergne Utilisation d'activateurs de canaux potassiques k2p en tant qu'antalgiques.
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
MX354476B (es) 2010-12-15 2018-03-07 Theravance Inc Inhibidores de neprilisina.
SI2651896T1 (sl) 2010-12-15 2015-11-30 Theravance Biopharma R&D Ip, Llc Inhibitorji neprilizina
MX342212B (es) 2011-02-17 2016-09-20 Theravance Inc Inhibidores de neprilisina.
US8449890B2 (en) 2011-02-17 2013-05-28 Theravance, Inc. Neprilysin inhibitors
CA2835216A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
WO2012166390A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
EP2714648B1 (de) 2011-05-31 2017-08-16 Theravance Biopharma R&D IP, LLC Neprilysin-inhibitoren
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
CN104350052B (zh) 2012-05-31 2017-05-31 施万生物制药研发Ip有限责任公司 一氧化氮供体脑啡肽酶抑制剂
US8871792B2 (en) 2012-06-08 2014-10-28 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
ME02698B (de) 2012-06-08 2017-10-20 Theravance Biopharma R&D Ip Llc Neprilysin-inhibitoren
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
MX2015000217A (es) 2012-06-28 2015-04-10 Mcneil Ppc Inc Composiciones lipidicas de racecadotrilo.
CN104520277B (zh) 2012-08-08 2018-01-19 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
ES2634218T3 (es) 2013-03-05 2017-09-27 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
JP2017507921A (ja) 2014-01-30 2017-03-23 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
US9585882B2 (en) 2014-01-30 2017-03-07 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril
MY187899A (en) 2015-02-11 2021-10-27 Theravance Biopharma R&D Ip Llc (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
JP6714009B2 (ja) 2015-02-19 2020-06-24 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー （２ｒ，４ｒ）−５−（５’−クロロ−２’−フルオロビフェニル−４−イル）−２−ヒドロキシ−４−［（５−メチルオキサゾール−２−カルボニル）アミノ］ペンタン酸
KR20220035991A (ko) 2016-03-08 2022-03-22 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 (2s,4r)-5-(5'-클로로-2'-플루오로-[1,1'-비페닐]-4-일)-2-(에톡시메틸)-4-(3-히드록시이속사졸-5-카르복사미도)-2-메틸펜탄산 결정 및 그 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4798904A (en) * 1983-10-03 1989-01-17 E. R. Squibb & Sons, Inc. Certain [(lower alkanoyl-thio)methyl-1-oxo-3-phenyl propyl amino]benzene lower alkanoic acid or ester derivatives which inhibit enkephalinase
FR2559770B1 (fr) * 1984-02-20 1986-10-24 Roussel Uclaf Nouveaux derives de n-alkyl-o-mercaptopropanamide, leurs procedes de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus
US4740499A (en) * 1986-07-28 1988-04-26 Monsanto Company Method of enhancing the bioactivity of atrial peptides
FR2623498B1 (fr) * 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques

Also Published As

Publication number Publication date
JP2537159B2 (ja) 1996-09-25
EP0318377A2 (de) 1989-05-31
EP0318377B1 (de) 1993-08-25
US5331008A (en) 1994-07-19
ES2059554T3 (es) 1994-11-16
DE3883495T2 (de) 1993-12-09
FR2623498B1 (fr) 1990-04-06
FR2623498A1 (fr) 1989-05-26
DE3883495D1 (de) 1993-09-30
US5208255A (en) 1993-05-04
EP0318377A3 (en) 1990-03-07
JPH0859606A (ja) 1996-03-05
JPH02161A (ja) 1990-01-05
US5296509A (en) 1994-03-22
JP2529172B2 (ja) 1996-08-28

Similar Documents

Publication Publication Date Title
DE3883495D1 (de) Enantiomere Derivate von Aminosäure, Verfahren zu deren Herstellung und deren therapeutische Verwendung.
DE122005000045I1 (de) R-Enantiomer von N-Propargyl-1-aminoindan, dessen Herstellung und dieses enthaltende pharmazeutischeZusammensetzungen.
FI906438A0 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten A-nor-steroidi-3-karboksyylihappojohdannaisten valmistamiseksi
ATE45728T1 (de) Verfahren zur herstellung bestimmter enantiomerenpaare von permethrinsaeure-alpha-cyano-3-phenoxy-4-fluor-b nzyl-ester.
DE3854004D1 (de) Verfahren zur Herstellung von N-substituiertem Amin.
DE69004648D1 (de) Verfahren zur Herstellung von Alpha-Hydroxycarbonsäure-Amiden.
DE69004582D1 (de) Verfahren zur Herstellung von alpha-Hydroxycarbonsäure-Amid.
ATA292078A (de) Verfahren zur herstellung von neuen 9-amino- desoxyclavulansaeurederivaten
DE59004490D1 (de) Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten.
AT368502B (de) Verfahren zur herstellung von neuen 1,3-dihydro- heteroarylspiro(isobenzofuran)en und von deren optischen antipoden und pharmazeutisch vertraeglichen saeureadditionssalzen
DE3678139D1 (de) Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung.
DE69011758D1 (de) Verfahren zur Herstellung von N-substituierten Maleinimiden.
DE69113323D1 (de) Verfahren zur Herstellung von alpha-Hydroxycarbonsäure amiden.
DE3888317D1 (de) Verfahren zur Herstellung von Phosphorsäurederivaten und Zwischenprodukten.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
DK574688A (da) Fremgangsmaade til fremstilling af propensyrederivater
DK498388D0 (da) Fremgangsmaade til fremstilling af propensyrederivater
ATE77378T1 (de) Verfahren zur herstellung von carbonsaeureamiden.
DK364386A (da) 1-alkyl-ergolinyl-thiourinstofderivater og fremgangsmaade til fremstilling deraf samt deres anvendelse
ATA134177A (de) Verfahren zur herstellung von racemischem und von optisch aktivem 1-tert. butylamino-3- (2',5'-dichlorphenoxy)-2-propanol und dessen saeureadditionssalzen
DK665888D0 (da) Fremgangsmaade til fremstilling af propansyrederivater
DE68928788T2 (de) Verfahren zur Herstellung von optisch aktiven 3,4-Dihydroxybuttersäurederivaten
DK160990C (da) Analogifremgangsmaade til fremstilling af n-(2-(5-dimethylaminomethylfuran-2-ylmethylthio)ethyl)-3-pyridin-carboxamid-1-oxid eller farmaceutisk acceptable syreadditionssalte deraf
DE58907865D1 (de) Verfahren zur Herstellung von alpha-Ketocarbonsäureestern.
DK152384A (da) Fremgangsmaade til fremstilling af to enantiomere af gamma-glutamyl-taurin, den racemiske blanding og farmaceutisk anvendelige salte deraf

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time